Literature DB >> 7067062

Interaction of adriamycin in vitro with cardiac myofibrillar proteins.

W Lewis, J Kleinerman, S Puszkin.   

Abstract

Binding of the anthracycline antibiotic doxorubicin [Adriamycin (ADR)] to selected cardiac muscle contractile proteins was determined in purified canine heart actin and alpha-actinin. Adriamycin binding to these proteins in solution was measured by equilibrium dialysis and gel filtration with [14C]-labeled ADR. Adriamycin did not bind when its primary amino group was blocked. Adriamycin binding did not affect actin polymerization as detected by viscometry. Viewed under the electron microscope, however, ADR promoted formation of distinct actin filaments in the presence of microM amounts of ATP without K+ and MG++. Adriamycin-induced actin microfilaments were thicker (120 A) than those of F-actin controls (70 A) and stimulated myosin-ATPase to higher levels than the F-actin controls. It appears that ADR has a direct effect on the biophysical and biochemical properties of heart myofibril proteins in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7067062     DOI: 10.1161/01.res.50.4.547

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  4 in total

Review 1.  Doxorubicin effects on contractile structures and molecules.

Authors:  R Colombo; A Milzani; A Necco; G Vailati
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

2.  Cardiotoxic effects of anthracyclines.

Authors:  M R Bristow
Journal:  West J Med       Date:  1983-09

3.  Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity.

Authors:  J A Jackson; J P Reeves; K H Muntz; D Kruk; R A Prough; J T Willerson; L M Buja
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

4.  Anthracyclines selectively decrease alpha cardiac actin mRNA abundance in the rat heart.

Authors:  T Papoian; W Lewis
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.